| The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells RM Melillo, MD Castellone, V Guarino, V De Falco, AM Cirafici, ... The Journal of clinical investigation 115 (4), 1068-1081, 2005 | 423 | 2005 |
| Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics U Anand, A Dey, AKS Chandel, R Sanyal, A Mishra, DK Pandey, ... Genes & Diseases 10 (4), 1367-1401, 2023 | 278 | 2023 |
| BRAF is a therapeutic target in aggressive thyroid carcinoma G Salvatore, V De Falco, P Salerno, TC Nappi, S Pepe, G Troncone, ... Clinical Cancer Research 12 (5), 1623-1629, 2006 | 213 | 2006 |
| Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas MD Castellone, V Guarino, V De Falco, F Carlomagno, F Basolo, ... Oncogene 23 (35), 5958-5967, 2004 | 181 | 2004 |
| Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer V De Falco, V Guarino, E Avilla, MD Castellone, P Salerno, G Salvatore, ... Cancer research 67 (24), 11821-11829, 2007 | 146 | 2007 |
| Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness V Guarino, P Faviana, G Salvatore, MD Castellone, AM Cirafici, ... The Journal of Clinical Endocrinology & Metabolism 90 (9), 5270-5278, 2005 | 126 | 2005 |
| Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells P Salerno, V De Falco, A Tamburrino, TC Nappi, G Vecchio, ... The Journal of Clinical Endocrinology & Metabolism 95 (1), 450-455, 2010 | 120 | 2010 |
| The β-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation MD Castellone, V De Falco, DM Rao, R Bellelli, M Muthu, F Basolo, ... Cancer research 69 (5), 1867-1876, 2009 | 113 | 2009 |
| Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer V De Falco, P Buonocore, M Muthu, L Torregrossa, F Basolo, M Billaud, ... The Journal of Clinical Endocrinology & Metabolism 98 (5), E811-E819, 2013 | 108 | 2013 |
| Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets A Cerrato, V De Falco, M Santoro Journal of molecular endocrinology 43 (4), 143, 2009 | 96 | 2009 |
| XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway M Lodyga, V De Falco, XH Bai, A Kapus, RM Melillo, M Santoro, M Liu Oncogene 28 (7), 937-949, 2009 | 83 | 2009 |
| CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells V De Falco, A Tamburrino, S Ventre, MD Castellone, M Malek, SN Manié, ... Cancer research 72 (6), 1449-1458, 2012 | 82 | 2012 |
| The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells D Vitagliano, V De Falco, A Tamburrino, S Coluzzi, G Troncone, ... Endocrine-related cancer 18 (1), 1-11, 2011 | 81 | 2011 |
| RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase V De Falco, MD Castellone, G De Vita, AM Cirafici, JM Hershman, ... Cancer research 67 (1), 381-390, 2007 | 81 | 2007 |
| Biochemical and molecular characterization of the novel BRAFV599Ins mutation detected in a classic papillary thyroid carcinoma S Moretti, A Macchiarulo, V De Falco, N Avenia, F Barbi, C Carta, ... Oncogene 25 (30), 4235-4240, 2006 | 77 | 2006 |
| Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E MH Lee, SE Lee, DW Kim, MJ Ryu, SJ Kim, SJ Kim, YK Kim, JH Park, ... The Journal of Clinical Endocrinology & Metabolism 96 (1), E19-E30, 2011 | 69 | 2011 |
| Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes MD Castellone, AM Cirafici, GD Vita, VD Falco, L Malorni, G Tallini, ... Oncogene 22 (2), 246-255, 2003 | 54 | 2003 |
| XB130 mediates cancer cell proliferation and survival through multiple signaling events downstream of Akt A Shiozaki, G Shen-Tu, X Bai, D Iitaka, V De Falco, M Santoro, ... Public Library of Science 7 (8), e43646, 2012 | 49 | 2012 |
| The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial … RM Melillo, AM Cirafici, V De Falco, M Bellantoni, G Chiappetta, A Fusco, ... The American journal of pathology 165 (2), 511-521, 2004 | 48 | 2004 |
| Fragment‐based discovery of a dual pan‐RET/VEGFR2 kinase inhibitor optimized for single‐agent polypharmacology B Frett, F Carlomagno, ML Moccia, A Brescia, G Federico, V De Falco, ... Angewandte Chemie 127 (30), 8841-8845, 2015 | 44 | 2015 |
